Wald family-linked fund seeks another Oncoclínicas board overhaul
UBS Lumen, which owns 4.93% of the company, wants to replace five of seven directors as…
We don’t have a company profile for ONCO3 yet. The quote and chart come from TradingView. Browse the companies we cover in the Stock Guide.
UBS Lumen, which owns 4.93% of the company, wants to replace five of seven directors as…
Funds want to temporarily suspend shareholder rights held by the Centaurus-linked vehicle until it complies with…
ONCO3 jumped from R$0.56 to R$1.10 in seven days as daily trading activity nearly quadrupled; a…
Latache’s appeal will be decided by three members of the regulator’s board; Marina Copola has recused…
A 90-day injunction bars provider-network removals and commercial changes; industry source says it creates “contractual immunity”…
Proposal includes convertible debentures and usufruct rights over shares, but amounts to less than 10% of…
Minority shareholders challenge the process, the role of outside legal opinions, and are preparing an appeal…
A BTG Pactual survey shows ten listed healthcare companies increased their combined workforce from about 166,000…
Company halts outlook citing macro pressures and recent results, removing key visibility for investors.
Market data by TradingView. Informational only — not investment advice.